This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
EMERYVILLE, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biotechnology company focused on the topical, anti-infective market, today announced that Ron Najafi, Ph.D., Chairman and CEO of NovaBay Pharmaceuticals, will present a corporate and clinical update at the 8th Annual JMP Securities Healthcare Conference, held July 9-10, 2013 in New York City. Ron Najafi and Tom Paulson, Chief Financial Officer of NovaBay, will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.
JMP Securities Healthcare Conference
Wednesday, July 10, 2013
4:00 pm EDT
New York City
To access the live audio webcast of this presentation, please log on through a link located in the News & Events section of NovaBay's website at
http://novabay.com/investors/events . A replay of the webcast will be available one hour after the conclusion of the live event.
About NovaBay Pharmaceuticals, Inc.Going Beyond Antibiotics
NovaBay Pharmaceuticals is a biotechnology company focused on addressing the large unmet therapeutic needs of the global, topical anti-infective market with auriclosene. The Company's four core business units – DermaBay, UroBay, EyeBay and MediBay – are developing products in dermatology, urology, ophthalmology, and wound care areas.
CONTACT: NovaBay Pharmaceuticals Contacts
Thomas J. Paulson
Chief Financial Officer
Director, Investor Relations and Corporate Communications
NovaBay Pharmaceuticals, Inc.